Current treatments for ROP such as laser photocoagulation [10, 29], and intravitreal anti-VEGF therapy [10], target the neovascular and end-stage of the disease, and although moderately beneficial, are associated with significant sequelae including unknown systemic risks, adverse events such as retinal detachment or recurrence of ROP and compromised visual acuity. Here, VEGFA is linked to retinopathy of prematurity.